US OptionsDetailed Quotes
IDYA250516C12500
- 0.00
- 0.000.00%
15min DelayTrading May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover245.61%IV-31.60%PremiumMay 16, 2025Expiry Date5.78Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8943Delta0.0292Gamma3.05Leverage Ratio-0.0798Theta0.0020Rho2.72Eff Leverage0.0047Vega
IDEAYA Biosciences Stock Discussion
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial
Breakthrough: First-in-Class Cancer Drug Combination Shows Promise in Bladder Cancer Study
Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing
Major Clinical Trial Update: IDEAYA's Novel Cancer Drug Targets 48,000 Annual NSCLC Cases
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in...
📊⚡️📊
No comment yet